2 1 Shi Ji Jing Ji Bao Dao·2025-09-17 14:59Group 1 - Maiwei Biotech signed an exclusive licensing agreement with Kalexo Bio, potentially receiving up to $1 billion in upfront and milestone payments, along with low single-digit royalties [2] - The agreement allows Kalexo to exclusively develop, manufacture, and commercialize the 2MW7141 project, a dual-target small nucleic acid drug aimed at lipid regulation and cardiovascular event prevention [2] - The deal is expected to positively impact Maiwei's future performance and enhance profitability [2] Group 2 - China Ping An completed the purchase of 74.615 million H shares under its 2025 long-term service plan, accounting for 0.412% of the total share capital, with a total transaction value of 3.875 billion yuan [3] - The average transaction price was approximately 51.87 yuan per share, with 83,024 core talents voluntarily participating in the plan [3] - The holding ratio of directors, supervisors, and senior management in the plan is 2.52%, while other employees hold 97.48% [3] Group 3 - Top Group's actual controller and vice chairman decided to terminate their share reduction plan early, having reduced their holdings by a total of 349.36 million shares, or 0.201% of the total shares [4] - The early termination was due to the fulfillment of their personal funding needs [4] Group 4 - Haon Electric stated that its order amounts are based on customer sales forecasts, and actual order amounts may vary due to market changes [5] - The company is primarily engaged in the development, design, manufacturing, and sales of automotive intelligent driving perception systems, while its robotics business is still in the R&D stage [5] Group 5 - Pinming Technology announced a stock suspension due to planning a significant matter that may lead to a change in control [6][7] - The stock will be suspended for no more than two trading days, with timely announcements to follow regarding the matter's progress [7] Group 6 - Tianpu Co. completed its stock trading suspension investigation and will resume trading on September 18, 2025, after a period of price increases and abnormal trading [8] - The investigation confirmed that there are no asset injection plans from the rumored acquirer, Zhonghaoxin [8] Group 7 - Changchun High-tech's subsidiary, Jinsai Pharmaceutical, secured exclusive agency rights for three products in mainland China from Denmark's ALK-Abelló A/S [9] - Jinsai will pay an upfront fee of 32.7 million euros and additional milestone payments based on regulatory approval and sales performance [9]